✨ Free AI Report
Akebia Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Akebia Therapeutics, Inc.
Company Research

Akebia Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Akebia Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage commercial biotech with two approved kidney disease products facing revenue headwinds but supported by pipeline expansion and analyst optimism. Revenue declined 17.7% year-over-year in 2024 to $160.2M, while net losses increased 33.7% to $69.4M. However, analysts rate AKBA as "Strong Buy" with a 12-month target of $6.25, suggesting.

What is Akebia Therapeutics, Inc.'s industry? Akebia Therapeutics, Inc. (akebia.com) operates in Biopharmaceuticals - Nephrology/Kidney Disease Therapeutics. AskCyborg classifies Akebia Therapeutics, Inc. under Biopharmaceuticals - Nephrology/Kidney Disease Therapeutics in its company registry.

Akebia Therapeutics is a fully integrated biopharmaceutical company focused on addressing significant unmet needs for people living with kidney disease, positioning itself as a leader in the renal community. The compa...

4/ 10Mixed

Cyborg Score thesis

Early-stage commercial biotech with two approved kidney disease products facing revenue headwinds but supported by pipeline...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Nephrology/Kidney Disease Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Akebia Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Akebia Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Akebia Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Akebia Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Akebia Therapeutics, Inc. Overview

Pro stress-test →

Akebia Therapeutics is a fully integrated biopharmaceutical company focused on addressing significant unmet needs for people living with kidney disease, positioning itself as a leader in the renal community. The company has two commercial products for patients impacted by kidney disease: Vafseo and Auryxia.

Strategic Profile

Pro stress-test →

The company develops and commercializes novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. Akebia has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries.

Competitive Landscape

Pro stress-test →

Akebia is a fully integrated biopharmaceutical company focused on kidney disease. Competitors in the kidney disease therapeutics space include BioCryst, Esperion, Ironwood, and Ardelyx, each with differentiated approaches to CKD-related complications and anemia management.

Industry Context

Akebia Therapeutics, Inc. operates in Biopharmaceuticals - Nephrology/Kidney Disease Therapeutics.

Key facts

Founded: 2007 · Headquarters: Cambridge, Massachusetts, US · Employees: 181 · Revenue: $160.2M (2024) · Market cap: $321.1M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Akebia Therapeutics, Inc..

  • Vafseo (vadadustat) is FDA-approved for treating anemia due to chronic kidney disease in adult patients on dialysis for at least three months.
  • Company is developing AKB-9090 for cardiac surgery-related acute kidney injury and AKB-10108 for retinopathy of prematurity in neonates.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Akebia price target lowered to $4 from $5 at BTIG
  • January 2026Company announces corporate updates and 2026 pipeline outlook
  • +1 moreTrack every material event for Akebia Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Akebia Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

VeltassaPotassium binder for hyperkalemia in CKD→VenoferIntravenous iron supplement for anemia in CKD→EsperoctETC-1002 therapy for lipid management→

Compare Akebia Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Akebia Therapeutics, Inc. operates in Biopharmaceuticals - Nephrology/Kidney Disease Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Nephrology/Kidney Disease Therapeutics research →
NEW · MCP server

Ask your AI assistant about Akebia Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Akebia Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Akebia Therapeutics, Inc. do this quarter?”
“Is Akebia Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Akebia Therapeutics, Inc. do?+
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on addressing significant unmet needs for people living with kidney disease, positioning itself as a leader in the renal community. The compa...
What is Akebia Therapeutics, Inc.'s Cyborg Score?+
Akebia Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Akebia Therapeutics, Inc.'s main competitors?+
Named competitors include Veltassa, Venofer, Esperoct. The full competitive landscape is in the AskCyborg report.
How can I get the full Akebia Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Akebia Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Akebia Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.